Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
AACR: Detailed data spark hope for Merck combo in NSCLC
Researchers plan to run biomarker analyses of patients in the KEYLYNK-008 trial to see whether any subsets may benefit from the addition of Lynparza.
Angus Liu
Apr 9, 2024 1:16pm
BMS touts KRAS confirmatory trial win after Amgen's stumble
Mar 29, 2024 10:35am
Merck’s Lynparza-Keytruda plan sputters in 2nd lung cancer trial
Mar 21, 2024 10:28am
J&J's Rybrevant moves into first line in lung cancer subtype
Mar 4, 2024 11:13am
Gilead secures $210M from Abingworth to fund Trodelvy trials
Feb 29, 2024 10:31am
AZ touts lung cancer advances for Tagrisso, ADC
Feb 20, 2024 1:09pm